新型SNOMED CT国际医药产品模型。

CEUR workshop proceedings Pub Date : 2018-12-01
Olivier Bodenreider, Julie James
{"title":"新型SNOMED CT国际医药产品模型。","authors":"Olivier Bodenreider,&nbsp;Julie James","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To present the new SNOMED CT international medicinal product model.</p><p><strong>Methods: </strong>We present the main elements of the model, with focus on types of entities and their interrelations, definitional attributes for clinical drugs, and categories of groupers.</p><p><strong>Results: </strong>We present the status of implementation as of July 2018 and illustrate differences between the original and new models through an example.</p><p><strong>Conclusions: </strong>Benefits of the new medicinal product model include comprehensive representation of clinical drugs, logical definitions with necessary and sufficient conditions for all medicinal product entities, better high-level organization through distinct categories of groupers, and compliance with international standards.</p>","PeriodicalId":72554,"journal":{"name":"CEUR workshop proceedings","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584358/pdf/nihms-1840460.pdf","citationCount":"0","resultStr":"{\"title\":\"The New SNOMED CT International Medicinal Product Model.\",\"authors\":\"Olivier Bodenreider,&nbsp;Julie James\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To present the new SNOMED CT international medicinal product model.</p><p><strong>Methods: </strong>We present the main elements of the model, with focus on types of entities and their interrelations, definitional attributes for clinical drugs, and categories of groupers.</p><p><strong>Results: </strong>We present the status of implementation as of July 2018 and illustrate differences between the original and new models through an example.</p><p><strong>Conclusions: </strong>Benefits of the new medicinal product model include comprehensive representation of clinical drugs, logical definitions with necessary and sufficient conditions for all medicinal product entities, better high-level organization through distinct categories of groupers, and compliance with international standards.</p>\",\"PeriodicalId\":72554,\"journal\":{\"name\":\"CEUR workshop proceedings\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584358/pdf/nihms-1840460.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CEUR workshop proceedings\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CEUR workshop proceedings","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:建立新的SNOMED CT国际医药产品模型。方法:我们提出了模型的主要元素,重点是实体类型及其相互关系,临床药物的定义属性和石斑鱼的类别。结果:我们介绍了截至2018年7月的实施情况,并通过一个例子说明了原模型与新模型的差异。结论:新药品模型的好处包括临床药品的全面表征,所有药品实体具有必要和充分条件的逻辑定义,通过不同类别的石头鱼更好的高层组织,以及符合国际标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The New SNOMED CT International Medicinal Product Model.

The New SNOMED CT International Medicinal Product Model.

The New SNOMED CT International Medicinal Product Model.

Objectives: To present the new SNOMED CT international medicinal product model.

Methods: We present the main elements of the model, with focus on types of entities and their interrelations, definitional attributes for clinical drugs, and categories of groupers.

Results: We present the status of implementation as of July 2018 and illustrate differences between the original and new models through an example.

Conclusions: Benefits of the new medicinal product model include comprehensive representation of clinical drugs, logical definitions with necessary and sufficient conditions for all medicinal product entities, better high-level organization through distinct categories of groupers, and compliance with international standards.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信